Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division ... Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States. Show more
Intel (NASDAQ:INTC), Apollo Global Management (NYSE:APO), Qualcomm (NASDAQ:QCOM) – Apollo Global Management has reportedly offered up to $5 billion to invest in Intel, according to Bloomberg. The...
Allegations of ballot manipulation, legal precedent and forum shopping pose major obstacles to company’s plan Attorneys representing tens of thousands of women with ovarian cancer linked to use...
Approximately 83% of Current Claimants and the Future Claims Representative Support the Proposed Bankruptcy Plan Red River Increased its Settlement Commitment by $1.75 Billion to Approximately...
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated...
Microsoft (NASDAQ:MSFT), Vodafone (NASDAQ:VOD) – Microsoft announced a new stock buyback program of up to $60 billion and a 10% increase in its quarterly dividend to $0.83. The company plans to...
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer PR Newswire BARCELONA...
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer PR Newswire BARCELONA, Spain, Sept. 15, 2024...
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer PR Newswire BARCELONA, Sept. 14, 2024 Median duration of response reaches 7.4...
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer PR Newswire BARCELONA, Sept...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.1311 | -1.88212310652 | 166.36 | 168.35 | 163.21 | 6353207 | 165.48534933 | CS |
4 | -1.0611 | -0.645870107736 | 164.29 | 168.85 | 162.16 | 6123482 | 165.46291841 | CS |
12 | 17.0589 | 11.6705890402 | 146.17 | 168.85 | 144.5 | 6680790 | 159.29083175 | CS |
26 | 7.8789 | 5.07170904409 | 155.35 | 168.85 | 143.13 | 7174558 | 153.51901194 | CS |
52 | 3.1589 | 1.97344911601 | 160.07 | 168.85 | 143.13 | 7100185 | 154.8627794 | CS |
156 | -1.2611 | -0.766672746064 | 164.49 | 186.69 | 143.13 | 8563620 | 164.39690063 | CS |
260 | 32.2089 | 24.5831934056 | 131.02 | 186.69 | 109.16 | 8154532 | 158.96969763 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.